Paper Details

  1. Home
  2. Paper Details

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.

Author: BerdelWolfgang, BuchnerThomas, GassmannWinfried, HaferlachTorsten, HeineckeAchim, HiddemannWolfgang, KernWolfgang, LofflerHelmut, SauerlandMaria Christina, SchochClaudia

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

In a study of 449 people with acute myeloid leukemia (AML), the amount of leukemia cells remaining in the bone marrow one week after starting treatment was a strong predictor of how well people responded to treatment and their long-term survival. Higher levels of leukemia cells at one week were associated with lower remission rates, shorter survival, and a higher risk of the cancer returning. These factors were independent of other factors, such as age and chromosome structure, and remained important even in those who achieved remission.
Paper Details　
Original Abstract of the Article :
Risk assessment in acute myeloid leukemia (AML) using pretreatment characteristics may be improved by incorporating parameters of early response to therapy. In the 1992 trial of the German AML Cooperative Group (AMLCG), the amount of residual leukemic blasts in bone marrow was assessed one week afte...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/12393605

データ提供：米国国立医学図書館（NLM）

Early Detection: A Game-Changer for Acute Myeloid Leukemia (AML)

AML, a type of blood cancer, can be a real desert trek for patients. This research focuses on finding oases, or early indicators, that can help us navigate this challenging terrain. The study used a technique called "day 16 blasts" to assess the amount of leukemia cells in the bone marrow a week after the first round of treatment. They discovered that a lower amount of blasts at day 16 was a key factor in predicting a higher chance of complete remission and a longer survival time. This is like finding a wellspring in the middle of a sandstorm—it can make all the difference.

Day 16 Blasts: A Beacon of Hope

The results show that day 16 blasts are a significant indicator of success. Patients with a lower number of blasts at day 16 had a much higher chance of achieving complete remission, which means the leukemia cells were eradicated. This discovery is like finding a guiding star in the night sky—it offers hope and direction for patients.

Early Detection: A Key to Personalized Treatment

This research highlights the importance of early detection and personalized treatment in AML. By closely monitoring patients and identifying key factors like day 16 blasts, doctors can tailor treatment plans to each individual's needs. This is like having a map that shows the most efficient route to recovery—a map that can lead us to a brighter future.

Dr.Camel's Conclusion

This research is like an oasis in the desert of AML research, providing us with a vital source of information. By understanding the significance of early detection, we can empower patients and doctors to navigate the complex landscape of this disease with greater precision and hope.

Date :
  1. Date Completed 2003-03-18
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

12393605

DOI: Digital Object Identifier

S0006-4971(20)53563-5

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.